Bimal Shah joins Corium, a commercial-stage CNS biopharma and Gurnet Point Capital investment, as Chief Financial Officer, bringing with him substantial experience in healthcare private equity investments, M&A, and other strategic transactions.  He also has industry experience in corporate strategy and commercial assessments with expertise in specialty pharmaceuticals, biotech, medical devices, contract research and manufacturing services, clinical and lab services, and distribution.

Prior to joining Corium, Bimal served as Senior Vice President, Corporate Finance and Strategy, for Sumitovant Biopharma, a wholly-owned subsidiary of Sumitovant Dainippon Biopharma, one of Japan’s largest pharmaceutical companies. While at Sumitovant, he had oversight for financial planning and analysis, corporate finance and strategy, among other responsibilities.

Bimal previously held roles in the business development, finance and strategic functions at various biotech companies, including Genentech. His earlier career occurred on Wall Street with Goldman Sachs and Warburg Pincus, where he focused on the life sciences and healthcare verticals and was responsible for a wide range of creative transactions, including financings, investments, acquisitions and alliances.